14 August 2016
Visiongain’ has launched a new pharma report Pharma Leader Series: Top Generic Drug Producers Market Forecast 2017-2027: North America, Europe, India, Japan, South Africa, MENA.
With patent expiries of blockbuster drugs, the generic drugs industry grows more important to the overall pharmaceutical market. Big Pharma are now realising the potential of generics to become a leading source of revenue over the next 10 years. The increasing penetration of generics in both developed and emerging markets has lead industry giants such as Novartis, Sanofi, Abbott and Pfizer to capitalise on this market. Visiongain’s study provides an assessment of the leading generic drug developers, producers and sellers, assessing their strategies and prospects from 2017.
The visiongain report analyst commented “Visiongain believes the forecast period will see more traditional pharma companies embrace generic business units in order to take advantage of higher growth rates in generics. At the same time, successful generic companies will try to innovate, pursuing more research-based pipeline candidates as well as high-value generics and biosimilars. However, generic drug manufacturers must continuously revise their business models in an attempt to outsmart market challenges. New strategic decisions will have to be made to define their future path. This may include steps such as merging for scale, complementing the generic portfolio with a branded portfolio, or adding new offerings and services in order to provide new revenue streams.
Taking advantage of the opportunities in this fast-growing, extremely competitive market will require generics manufacturers to sustain highly efficient production and distribution capacity and to expand their global presence through targeted acquisitions. Companies will need to be vigilant in taking advantage of growth sectors within the market, and aggressive in their pursuit of first-to-file applications”
Leading companies featured in the report who manufacture generic drugs include Teva, Mylan, Pfizer, Abbott, Novartis, Sanofi, Fresenius Kabi, Sun Pharmaceutical Industries, Dr. Reddy’s, Lupin, EMS, Cipla, Perrigo, Abdi Ibrahim and other leading companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.